PHR
Phreesia, Inc.
PHR has a slight edge over UNH overall, supported by stronger fundamentals.
UNH
UnitedHealth Group Incorporated
UNH has lower modeled downside risk, despite its lower overall score.
PHR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Healthy |
PHR's revenue, profitability, cash flow and balance sheet are all currently healthy.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
PHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $12.62 | — |
| Cheap | 59x | $10.60 | -16% |
| Fair | 68x | $12.27 | -2.8% |
| Current | 70x | $12.62 | — |
| Expensive | 215x | $38.67 | +206% |
Historical ranges are pointers, not guarantees.
PHR has the edge over UNH in the historical PE scenario, which offers more potential upside but is not a forecast.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
PHR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect PHR's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
PHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.62 | +245% |
| Q3 2026 | $0.18 | +$0.60 |
| Q2 2026 | $0.16 | +$0.90 |
| Q1 2026 | $0.04 | +$1.06 |
| Q4 2025 | -$0.10 | +$1.36 |
| Q3 2025 | -$0.42 | +$1.37 |
| Q2 2025 | -$0.74 | +$1.42 |
| Q1 2025 | -$1.02 | +$1.49 |
| Q4 2024 | -$1.46 | +$1.22 |
PHR has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
PHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $129.5M | +10% |
| Q2 2026 | $130.9M | +13% |
| Q1 2026 | $127.1M | +16% |
| Q4 2025 | $120.3M | +13% |
| Q3 2025 | $117.3M | +15% |
| Q2 2025 | $115.9M | +15% |
| Q1 2025 | $109.7M | +15% |
| Q4 2024 | $106.8M | +17% |
PHR has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.9% | +7.2 points |
| Q2 2026 | 5.2% | +8 points |
| Q1 2026 | -4.4% | +2.6 points |
| Q4 2025 | 3.1% | +16 points |
| Q3 2025 | -1.3% | +16 points |
| Q2 2025 | -2.8% | +16 points |
| Q1 2025 | -6.9% | +24 points |
| Q4 2024 | -13% | +22 points |
PHR has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
PHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $17.8M | +36% |
| Q2 2026 | $19.6M | +73% |
| Q1 2026 | $31.1M | +131% |
| Q4 2025 | $12.2M | +136% |
| Q3 2025 | $13.1M | +97% |
| Q2 2025 | $11.3M | +$12.9M |
| Q1 2025 | $13.5M | +$19M |
| Q4 2024 | $5.2M | +$12.7M |
PHR has the edge over UNH on cash flow, with more consistent year-over-year improvement.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
PHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +423K shares |
| 1 year | +1.3% | +778K shares |
| 3 years | +16% | +8.7M shares |
| 5 years | +24% | +11.9M shares |
| Available history | +75% | +26.7M shares |
PHR has 62M diluted shares, up 1.3% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over PHR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
PHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | 1.1x | Healthy |
| Q4 2025 | -4.9x | Net Cash |
| Q3 2025 | -44.5x | Net Cash |
PHR has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
PHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.4 | Neutral |
| Stochastic | 80.7 | Overbought |
PHR's weekly RSI is 57 (neutral) and its Stochastic is 81 (overbought).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
PHR PE vs Healthcare Sector
| Metric | PHR | Sector median | Relative |
|---|---|---|---|
| PE | 70x | 26x | 171% above |
| PE % | 56 | 29 | 27 pts above |
PHR is trading at 70x earnings, a 171% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH has the edge over PHR on valuation relative to its sector.
PHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.5 | 9.4% above |
| 20 week MA | $11.3 | 12% above |
| 50 week MA | $11.8 | 6.8% above |
| 100 week MA | $18.7 | 33% below |
| 200 week MA | $21.9 | 42% below |
PHR has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 42% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over PHR on trend strength, trading above more of its moving averages.
PHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.4 | $57.3 | +117% |
| 2021 | $57.3 | $44.2 | -23% |
| 2022 | $44.2 | $33.5 | -24% |
| 2023 | $33.5 | $23.2 | -31% |
| 2024 | $23.2 | $25.8 | +11% |
| 2025 | $25.8 | $17.0 | -34% |
| 2026 YTD | $17.0 | $12.6 | -26% |
PHR has finished lower in four of the last six years. It's down 26% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over PHR on returns for 2026, with the stronger performance.